Get Started Free
Home›Pharmaceuticals›Pfizer
Pfizer logo
Pfizer
Pharmaceuticals

Pfizer Company Overview

Pfizer logo

Pfizer

● Active
Pharmaceuticals · New York, NY · Est. 1849
PharmaceuticalsOncologyVaccinesBiotechRare Disease↗ Website
$148.5B
Valuation
$63.5B
Revenue
88k+
Employees
1849
Founded

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines, vaccines, and consumer healthcare products across oncology, internal medicine, vaccines, and rare disease. It serves patients in over 125 countries through a portfolio spanning blockbuster drugs like Eliquis and Paxlovid to cutting-edge antibody-drug conjugates acquired through its $43B Seagen transaction.

Recent Press
5 items
Product Launch·2025-12-16
Pfizer Plans 15 New Obesity Drug Trials in 2026 from Metsera Pipeline
Pfizer announced plans to begin 15 new obesity drug trials in 2026, predominantly Phase 3 studies of ultra-long-acting GLP-1 candidates from the Metsera acquisition, as part of 20 pivotal studies planned across oncology and metabolic disease.
Press Release·2025-12-16
Pfizer Projects 2026 Revenue of $59.5B-$62.5B Amid Pipeline Rebuild
Pfizer guided 2026 revenues of $59.5 billion to $62.5 billion, representing roughly flat growth versus 2025, as the company invests heavily in a pipeline refresh across obesity, oncology, and immunology to reduce Paxlovid dependence.
Acquisition·2025-11-15
Pfizer Acquires Metsera for $4.9B to Enter Obesity Drug Market
Pfizer won a bidding war against Novo Nordisk for obesity drugmaker Metsera Inc., closing the $4.9 billion acquisition in November 2025 at $47.50 per share, gaining a portfolio of next-generation ultra-long-acting GLP-1 obesity medicines.
Press Release·2025-10-30
Pfizer Cuts 11 Pipeline Programs Including Seagen Assets in R&D Restructuring
Pfizer discontinued 11 drug development programs in late 2025, including several assets acquired through the $43 billion Seagen deal, as the company refocused its oncology R&D investment on the highest-probability candidates.
Partnership·2025-08-10
Pfizer Licenses PD-1/VEGF Cancer Drug from 3SBio for $1.25B Upfront
Pfizer paid 3SBio $1.25 billion upfront for rights outside China to SSGJ-707, a dual PD-1/VEGF inhibitor with potential for up to $4.8 billion in additional milestone payments if the oncology therapy achieves clinical and commercial targets.
Company History
10 milestones
German-American cousins Charles Pfizer and Charles Erhart founded Charles Pfizer & Company in Brooklyn, New York, manufacturing their first product — a palatable antiparasitic drug called santonin blended with almond toffee — and quickly pivoting to supply citric acid and other industrial chemicals.

Pfizer Organization Structure & Team

Org Chart
88,000 employees · Click a leader to explore their team
86,000 across 12 departments
Chief Executive Officer
Albert Bourla
David Denton — Departments
· 86000 people across 12 depts

Pfizer Financials, Revenue & Market Share

Annual Revenue
$63.5B
0% vs prior year
YoY Growth
0%
From $81.3B to $63.5B
Revenue / Employee
$722K
Annual revenue per full-time employee
Revenue Growth
2021
2022
2023
2024
2025
$81.3B
$100.3B
$58.5B
$63.6B
$63.5B
Market Share
Global Branded Pharmaceuticals
7%
share
Pfizer
7%
MSD / Merck
6%
Roche
6%
AbbVie
6%
Johnson & Johnson
5%
$1.6T
TAM
$420B
SAM
$63.6B
SOM
Revenue Streams
Oncology28%
Internal Medicine32%
Vaccines22%
Hospital & Sterile Injectables10%
Rare Disease & Other8%
Business Units
Biopharmaceuticals90%
Pfizer's core segment covering oncology, internal medicine, vaccines, and rare disease — encompassing all marketed medicines and vaccines including newly integrated Seagen ADC products.
Hospital & Contract Manufacturing10%
Sterile injectable manufacturing for hospital critical care, Pfizer CentreOne CDMO services, and biosimilars produced under licensing arrangements for global markets.

Pfizer Internal Tools & Processes

Internal Tools
12 departments
Oncology6000 people · 3 roles
Standards & Certifications
10 standards
Compliance frameworks, security audits, and quality certifications this company maintains.
Regulatory
FDA cGMP
Certified
Pfizer's global manufacturing sites — including facilities in Kalamazoo MI, McPherson KS, Freiburg Germany, and Dalian China — operate under FDA Current Good Manufacturing Practice regulations, subject to periodic FDA inspections and consent decree compliance monitoring to ensure medicine quality and patient safety.
Regulatory
EMA GMP
Certified
Pfizer's European manufacturing and supply chain operations comply with European Medicines Agency Good Manufacturing Practice guidelines, enabling commercialization of medicines across all 27 EU member states under a unified regulatory framework and allowing batch release of Comirnaty and Prevnar in European markets.
Quality
ICH Q10
Certified
Pfizer implements the ICH Q10 Pharmaceutical Quality System framework across its global R&D and manufacturing operations, integrating lifecycle management, change control, and continuous process verification into its production of biologics, small molecules, and antibody-drug conjugates.
Environmental
ISO 14001:2015
Certified
Pfizer holds ISO 14001:2015 certification for its Environmental Management System, supporting its goal to achieve net-zero greenhouse gas emissions across its global operations by 2040. The certification covers energy use, water consumption, and chemical waste management at manufacturing and research sites worldwide.
Safety
ISO 45001:2018
Certified
Pfizer's Occupational Health and Safety Management System is certified to ISO 45001:2018 across its manufacturing and laboratory facilities, governing workplace safety protocols for handling controlled substances, biological materials, and high-potency active pharmaceutical ingredients (HPAPIs) used in ADC production.
Quality
ISO 9001:2015
Certified
Pfizer maintains ISO 9001:2015 Quality Management System certification across its commercial manufacturing operations, ensuring consistent process quality for drug substance and drug product manufacturing, supplier qualification, and deviation management across Pfizer's complex global supply network.
Privacy
HIPAA
Compliant
Pfizer's clinical trial operations, patient support programs, and digital health platforms — including the Pfizer for Professionals portal and Paxlovid Patient Assistance Program — comply with HIPAA Privacy and Security Rules, protecting the health information of patients enrolled in commercial and compassionate use programs.
Regulatory
SOX
Compliant
As a publicly traded company on the NYSE, Pfizer complies with Sarbanes-Oxley Act (SOX) Section 302 and 404 requirements, maintaining rigorous internal controls over financial reporting across its 60+ country operations, external audited by KPMG on an annual basis.
Regulatory
PIC/S GMP
Certified
Pfizer's manufacturing facilities in participating countries operate under Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP standards, facilitating mutual recognition of inspections between PIC/S member regulators and enabling Pfizer to supply markets across North America, Europe, Australia, and Southeast Asia from shared manufacturing hubs.
Security
ISO 27001
Certified
Pfizer's information security management program is aligned with ISO/IEC 27001 standards, protecting sensitive clinical trial data, proprietary compound libraries, manufacturing batch records, and patient-identifiable information from cybersecurity threats — a critical posture following the high-profile 2020 COVID vaccine data breach attempt that Pfizer publicly disclosed.

Pfizer Interview Preparation

Interview Prep
Role-specific interview questions and keywords. Select a department, then click any role to prepare.
Oncology· 3 roles

Pfizer Products & Competitors

Product Suite
5 products · select one to explore
Pharmaceuticals
Pharmaceutical
Eliquis
The most prescribed oral anticoagulant in the U.S.

Eliquis (apixaban) is a Factor Xa inhibitor co-developed with Bristol Myers Squibb for stroke prevention in non-valvular atrial fibrillation and treatment and prevention of deep vein thrombosis and pulmonary embolism. It is the world's top-selling anticoagulant, with clinical superiority demonstrated in the ARISTOTLE and AMPLIFY trials across bleeding risk, stroke reduction, and all-cause mortality.

Use Cases
Prescribing Eliquis for stroke prevention in non-valvular AF patients transitioning off warfarin who are unsuitable for dose-monitoring requirementsInitiating Eliquis for acute DVT treatment in orthopedic post-surgical patients eligible for direct oral anticoagulant therapyManaging patients with AF and moderate CKD on Eliquis using renal dose-adjustment guidance from the ARISTOTLE subgroup analysis
No image
Key Customers
KP
Kaiser Permanente
VA
Veterans Affairs
ESI
Express Scripts
Competitive Intelligence
VSXarelto (rivaroxaban)
THEM

Xarelto is a once-daily oral Factor Xa inhibitor co-developed by Bayer and Johnson & Johnson for AF stroke prevention, DVT/PE treatment, and reduction of major cardiovascular events in coronary or peripheral artery disease patients.

EDGE

ARISTOTLE trial demonstrated Eliquis reduced stroke, major bleeding, and all-cause mortality vs. warfarin — the only DOAC to show mortality benefit in a head-to-head warfarin trial

VSPradaxa (dabigatran)
THEM

Pradaxa is a twice-daily direct thrombin inhibitor developed by Boehringer Ingelheim, indicated for AF stroke prevention and VTE treatment, and notable for being the first DOAC approved in the U.S.

EDGE

Eliquis demonstrates statistically lower major bleeding rates vs. Pradaxa in indirect comparisons and real-world database analyses

VSSavaysa (edoxaban)
THEM

Savaysa (edoxaban) is a once-daily Factor Xa inhibitor developed by Daiichi Sankyo, approved for AF stroke prevention and VTE treatment, with ENGAGE AF-TIMI 48 trial data showing non-inferiority vs. warfarin.

EDGE

Eliquis has the broadest label across NVAF, DVT treatment, PE treatment, and recurrent VTE prevention with the most real-world safety data

Related Companies

Merck & Co. logo
Merck & Co.
Pharmaceuticals
Merck & Co. is a global biopharmaceutical company discovering, developing, and delivering innovative medicines and vaccines across oncology, infectious disease, cardiovascular, and immunology. Best known for Keytruda — the world's best-selling cancer immunotherapy — and Gardasil, the leading HPV vaccine, Merck serves patients in more than 140 countries through its pharmaceutical and animal health divisions.